1) Nohria A, Tsang SW, Fang JC, et al. Clinical assess-ment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003 ; 41 : 1797.
2) Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure : a randomized controlled trial. JAMA 2004 ; 291(16) : 1963.
3) Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral va-sopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. JAMA 2007 ; 297 (12) : 1332.
4) Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 2007 ; 297 (12) : 1319.
5) Udelson JE, Orlandi C, Ouyang J, et al. Acute he-modynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction : an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008 ; 52 (19) : 1540.